Article
Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution.
NEJM evidence - 1 Jun 2026
Civettini Ivan, Malighetti Federica, Villa Matteo, Crippa Valentina, Aroldi Andrea, Cavalca Fabrizio, Graudenzi Alex, Lanino Luca, Maggioni Giulia, Haferlach Torsten, Fenaux Pierre, Platzbecker Uwe, Díez-Campelo María, Borin Lorenza Maria, Fumagalli Monica, Zappaterra Arianna, Manghisi Beatrice, Al Ali Najla H, Sallman David A, Padron Eric, Xie Zhuoer, Chan Onyee, Zeidan Amer M, Mologni Luca, Piazza Rocco, Komrokji Rami S, Della Porta Matteo Giovanni, Gambacorti-Passerini Carlo, Ramazzotti Daniele
Abstract excerpt
BACKGROUND: Myelodysplastic syndromes are clonal hematopoietic stem cell disorders characterized by multistep molecular evolution and a variable risk of leukemic transformation. Given this prognostic heterogeneity, accurate risk stratification is essential for clinical decision-making. We developed ProgEvo, a proprietary framework that infers molecular evolutionary trajectories and integrates them with clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
